WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Americans say discussions about clinical trials should be part of standard of care

Details
Development
25 July 2017
An overwhelming majority of Americans (86%) agree that health care professionals should discuss clinical trials with patients diagnosed with a disease as part of their standard of care, according to a new national public opinion survey commissioned by Research!America. And three-quarters of respondents (75%) agree that taking part in clinical trials is as valuable to our health care system as giving blood. But Americans are split on whether it's important for everyone to take part in a clinical trial if they are asked - 44% agree while 45% disagree and 12% are not sure.
Read more ...

27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next 5 years

Details
Development
20 July 2017
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented at the Alzheimer's Association International Conference (AAIC) by ResearchersAgainstAlzheimer's (RA2), an UsAgainstAlzheimer's network. The pipeline analysis offers projections for drugs currently in Phase II and Phase III clinical trials and identifies critical milestones in drug development, including estimated trial completion, estimated regulatory filing and estimated launch date.
Read more ...

Older Americans don't get - or seek - enough help from doctors & pharmacists on drug costs

Details
Development
30 June 2017
The majority of Americans over age 50 take two or more prescription medicines to prevent or treat health problems, and many of them say the cost weighs on their budget, a new poll finds. But many older adults aren't getting - or asking for - as much help as they could from their doctors and pharmacists to find lower-cost options, the new data reveal.
Read more ...

Noted experts critically evaluate benefits of medical marijuana for treatment of epilepsy

Details
Development
24 May 2017
Although cannabis had been used for many centuries for treatment of seizure disorders, medical use became prohibited in the 20th century. However, with the loosening of laws regarding medical marijuana, research and clinical use of marijuana-derived substances are increasing. This has prompted the editors of Epilepsy & Behavior to produce a special issue that presents an in-depth assessment of the potential of cannabinoids for the effective treatment of epilepsy. Cannabinoids are components of the cannabis plant.
Read more ...

Just one alcoholic drink a day increases breast cancer risk, exercise lowers risk

Details
Development
23 May 2017
Drinking just one glass of wine or other alcoholic drink a day increases breast cancer risk, finds a major new report by the American Institute for Cancer Research (AICR) and the World Cancer Research Fund (WCRF). The report also revealed, for the first time, that vigorous exercise such as running or fast bicycling decreases the risk of both pre- and post-menopausal breast cancers. Strong evidence confirmed an earlier finding that moderate exercise decreases the risk of post-menopausal breast cancer, the most common type of breast cancer.
Read more ...

Alzheimer's experts call for changes in FDA drug approval standards

Details
Development
12 May 2017
Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, "Single Endpoint for New Drug Approvals for Alzheimer's Disease," urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer's disease.
Read more ...

The accidental discovery of LSD

Details
Development
11 April 2017
Bicycle Day on April 19 honors not the two-wheeled mode of transportation, but the colorful ride taken by Swiss chemist Albert Hoffman who accidentally discovered LSD 74 years ago. In search of new medicines, Hoffman was trying to stabilize lysergic acid, a derivative of a fungal compound used in a migraine medicine. He ended up synthesizing a compound called lysergic acid diethylamine, or LSD. Later, he accidentally exposed himself to it and felt dizzy with hallucinations.
Read more ...

More Pharma News ...

  1. TB Alliance sublicenses promising anti-tuberculosis drug from the Medicines Patent Pool
  2. Your computer can help scientists search for new childhood cancer treatments
  3. Reshaping the future of global clinical trials practice
  4. 2016 Nobel Prize in Physiology or Medicine to Yoshinori Ohsumi
  5. CHIC Project Survey: Your Opinion Counts
  6. Global superbug response needs $5bn each year, experts predict
  7. Nature publication describes first example of a clinically applicable and systemic mRNA cancer immunotherapy vaccine
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Development
  4. GE Healthcare and M+W Group form strategic alliance in vaccines, insulin and biopharmaceuticals

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.